Comprehensive Searching for Circulating mircoRNAs as a Novel Biomarker for Pulmonary Arterial Hypertension
Project/Area Number |
16K09474
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Cardiovascular medicine
|
Research Institution | Nagasaki University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
池田 聡司 長崎大学, 医歯薬学総合研究科(医学系), 講師 (10336159)
前村 浩二 長崎大学, 医歯薬学総合研究科(医学系), 教授 (90282649)
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 肺動脈性肺高血圧症 / バイオマーカ / micro RNA / microRNA / アポトーシス / 膠原病性肺高血圧症 / biomarker / 臨床血管学 |
Outline of Final Research Achievements |
Pulmonary arterial hypertension(PAH) is a frequent complication in connective tissue diseases (CTD) and is associated with a high degree of mortality. Micro RNAs(miRNAs) function in various cellular activities. However, the role of miRNA in connective tissue disease-pulmonary arterial hypertension (CTD-PAH) is not fully understood. We assessed the hypothesis that whether serum miRNA expression can serve as a novel biomarker of CTD-PAH and evaluates the possibility that miRNA is involved in the pathogenesis of CTD-PAH. The expression miR-4674 was increased in the patients with CTD-PAH. High miR-4674 expression correlated with mean PA pressure. Next, we investigated the gain and loss of miR-4674 function by analyzing the bioactivity of pulmonary arterial smooth muscle cells (hPASMC). miRNA-4674 increased cells proliferation and protect cells against apoptosis. Interference with this pathway may offer novel approaches to treating CTD-PAH.
|
Academic Significance and Societal Importance of the Research Achievements |
肺動脈性肺高血圧症(PAH)は、昨今、新しい治療薬が開発されてはいるが、いまだ予後不良の疾患である。特に膠原病性肺動脈性肺高血圧症(CTD-PAH)の予後は非常に悪い。本研究結果はCTD-PAHの早期発見が可能となり、予後の改善が可能となる、また、既存の治療薬とは異なる、新しいPAHの治療ターゲットとなり得る事が示唆され、CTD-PAHの患者の予後をさらに改善することが期待できる。
|
Report
(4 results)
Research Products
(10 results)
-
[Journal Article] Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.2018
Author(s)
Ikeda S, Koga S, Yamagata Y, Eguchi M, Sato D, Muroya T, Yonekura T, Tsuneto A, Yoshimuta T, Koide Y, Kawano H, Maemura K.
-
Journal Title
J Cardiol
Volume: 印刷中
Issue: 2
Pages: 120-127
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-